Biotechnology

HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update

* Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales growth. * R&D momentum persisted with promising developments in anti-FcRn antibodies HL161ANS and batoclimab, positioning them as potentially best-in-class treatments for lgG-mediated autoimmune diseases. * Anticip...

2024-03-21 19:00 1047

Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London

SHANGHAI, March 21, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, published "Mtoxin™ Payload Applied in IDDC™ ADC Platform Significant Increases Therapeutic Index and Overcome MultiDrug Resistance in Various Tumor" as poster ...

2024-03-21 14:11 1069

SK bioscience Exports Influenza Vaccine to Thailand, Entering Southern Hemisphere Market

* Company exported 440,000 doses to Thailand, marking its entry into the Southeast Asian market and the Southern Hemisphere market. * Company has obtained marketing authorizations in 12 countries, with additional approvals underway in 10 countries to expand its market worldwide. BANGKOK and S...

2024-03-21 13:24 1450

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

- TreeFrog Therapeutics demonstrates fast, sustained, full motor recovery in preclinical models for Parkinson's Disease cell therapy program using C-Stem™ proprietary technology[1] -   BORDEAUX, France, March 21, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with...

2024-03-21 07:30 1388

Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress

TAIZHOU, China, March 21, 2024 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and annual results for 2023. The company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", and achieved the following milestones and progre...

2024-03-21 00:22 2718

Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in he...

2024-03-20 20:30 2009

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

* ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology inthe United States * The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary efficacy of ATN-031 in patients with advanced solid tumor...

2024-03-20 20:30 2078

Origin Agritech Announces Breakthrough in High-Yield Corn Production Through Gene Editing

Inbred Line Yield Increased Over 50% in Trials BEIJING, March 20, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced a major breakthrough in corn production technology. Building on the Company's...

2024-03-20 20:00 1150

Innovent Announces 2023 Annual Results and Business Updates

A transformative year of strong performance and material innovation progress ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

2024-03-20 19:44 2889

Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies

Proceeds to Support Advancement of Engrail's Pipeline for Neuropsychiatric and Neurodevelopmental Disorders  SAN DIEGO, March 20, 2024 /PRNewswire/ -- Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to impro...

2024-03-20 11:00 1429

Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in he...

2024-03-20 08:30 1435

SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential

SHANGHAI, March 19, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative-driven biopharmaceutical company with entire industry chain, presented the clinical study data of the 9MW2821 for patients with cervical cancer as focused plenary oral presentation at the Society of Gynecologic Oncology ...

2024-03-19 22:00 1115

Samsung Medison and Bracco Imaging Forge Path with New Diagnostic Ultrasound Technology Agreement at ECR 2024

The collaboration aims to improve ultrasound contrast agent utilization and image resolution, streamline workflow, and enhance clinical benefits for users and patients. MILAN, March 19, 2024 /PRNewswire/ -- Samsung Medison (CEO, Mr. Yongkwan Kim) and Bracco Imaging (CEO, Dr. Fulvio Renoldi Bracc...

2024-03-19 18:00 1557

LifeSpan Vision Ventures Invests in SENISCA

NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter. The company has developed proprietary technology that har...

2024-03-19 17:00 1243

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

* The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; * The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse events; * The China new drug application submiss...

2024-03-19 10:24 1026

Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC

SHANGHAI, March 18, 2024 /PRNewswire/ -- Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement. BioGeometry is a digital biology pioneer company that specializes in AI-driven protein design and R&D platform. Sanyou Bio is a world-leading high-tec...

2024-03-19 08:00 894

Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)

ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major d...

2024-03-19 08:00 1509

Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal

* New supply contract to bring Lunit INSIGHT CXR to TeleDiag in France and Lunit INSIGHT MMG to the Central region branch of the Portuguese League Against Cancer SEOUL, South Korea, March 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diag...

2024-03-18 21:00 1235

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

* Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% * Net Profit Attributable to the Owners of the Company[1] Increased 9.0% to RMB9,607 Million; Diluted Earnings per Share (EPS) Increased 14.9% to RMB3.24 * Adjusted Non-IFRS Net Profit Att...

2024-03-18 20:32 1878

EDAN and GH Labs Collaborate to Develop AI-Enabled Ultrasound Devices

BELLEVUE, Wash., March 18, 2024 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, announces a collaboration with Global Health Labs, Inc. (GH Labs) to co-develop AI-enabled ultrasound devices. The ...

2024-03-18 19:45 1401
123456 ... 275